HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth

Stock News

Yesterday

VIVA BIOTECH (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.

According to the company's recently disclosed first-half results, China Merchants Securities noted that 26H1 revenue climbed 21.0% year-on-year, largely attributed to the significant contribution from the ramp-up of two new commercial CDMO projects at Langhua Pharma. Specifically, Langhua Pharma generated revenue of RMB 601 million in 26H1, up 47.0% year-on-year (52.2% at constant exchange rates).

Both key new commercial projects are progressing steadily. The peptide project has already achieved commercial launch and entered the stocking and volume ramp-up phase, while the small-molecule project is currently in the PPQ production stage with an expected commercial launch in 2027. Together, these projects are set to become the core growth drivers for the CDMO business in the coming years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1159200143"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159200143\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159200143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 11:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159200143","market":"nz","top_or_hot":-1,"title":"HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth","media":"Stock News","content":"<p><b>VIVA BIOTECH</b> (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.<br><br>According to the company's recently disclosed first-half results, China Merchants Securities noted that 26H1 revenue climbed 21.0% year-on-year, largely attributed to the significant contribution from the ramp-up of two new commercial CDMO projects at Langhua Pharma. Specifically, Langhua Pharma generated revenue of RMB 601 million in 26H1, up 47.0% year-on-year (52.2% at constant exchange rates).<br><br>Both key new commercial projects are progressing steadily. The peptide project has already achieved commercial launch and entered the stocking and volume ramp-up phase, while the small-molecule project is currently in the PPQ production stage with an expected commercial launch in 2027. Together, these projects are set to become the core growth drivers for the CDMO business in the coming years.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-09 11:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>VIVA BIOTECH</b> (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.<br><br>According to the company's recently disclosed first-half results, China Merchants Securities noted that 26H1 revenue climbed 21.0% year-on-year, largely attributed to the significant contribution from the ramp-up of two new commercial CDMO projects at Langhua Pharma. Specifically, Langhua Pharma generated revenue of RMB 601 million in 26H1, up 47.0% year-on-year (52.2% at constant exchange rates).<br><br>Both key new commercial projects are progressing steadily. The peptide project has already achieved commercial launch and entered the stocking and volume ramp-up phase, while the small-molecule project is currently in the PPQ production stage with an expected commercial launch in 2027. Together, these projects are set to become the core growth drivers for the CDMO business in the coming years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1159200143","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159200143","pubTimestamp":1788924624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIVA BIOTECH (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.According to the company's recently disclosed first-half...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK1574":"生物医药B类股","01477":"欧康维视生物-B","BK4139":"生物科技","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","KCAI":"KraneShares China Alpha Index ETF","CDMO":"Avid Bioservices, Inc.","BK4588":"碎股","01873":"维亚生物"},"translate_title":"港股快讯 | 朗华医药两个新CDMO商业项目推动营收增长，维华生物(01873)股价飙升逾5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"KCAI":1,"VXUS":1,"01873":1,"01477":1},"content_text":"VIVA BIOTECH (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.According to the company's recently disclosed first-half results, China Merchants Securities noted that 26H1 revenue climbed 21.0% year-on-year, largely attributed to the significant contribution from the ramp-up of two new commercial CDMO projects at Langhua Pharma. Specifically, Langhua Pharma generated revenue of RMB 601 million in 26H1, up 47.0% year-on-year (52.2% at constant exchange rates).Both key new commercial projects are progressing steadily. The peptide project has already achieved commercial launch and entered the stocking and volume ramp-up phase, while the small-molecule project is currently in the PPQ production stage with an expected commercial launch in 2027. Together, these projects are set to become the core growth drivers for the CDMO business in the coming years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}